GleamWall
中文EN

GWLL GOLDENWELL BIOTECH, INC.

Food and Kindred Products · OTC · SEC CIK 1800373 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-94.1%
TTM net income YoY-12.4%
TTM EPS YoY—
Revenue 3-yr CAGR-79.9%
Net income 3-yr CAGR—

Margins

Gross margin50.4%
Operating margin-88,556.1%
Net margin-94,542.4%
FCF margin—
EBITDA margin—

Returns

ROE-710.0%
ROA-58.1%
ROIC (approx.)-125.7%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets121.1%
Debt / equity—
Current ratio—
Interest coverage-14.65x

Cash quality & payout

Operating cash flow / net income0.89x
Accruals ratio-6.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$55$139
Cost of revenue$43$75
Gross profit$12$64
SG&A expense$113,338$123,162
Operating income-$113,326-$123,098
Interest expense$8,400$8,400
Pretax income—-$131,498
Income tax$0$0
Net income-$296,471-$131,498
EPS (diluted)0.000.00
Weighted avg. shares (diluted)99.00M99.00M
Banking
Noninterest expense—$8,400
Balance sheet
Cash & equivalents$26,775$49,404
Inventory$174,745$174,788
Total assets$36,120$224,192
Current liabilities$101,860$1,860
Long-term debt—$173,985
Total debt—$173,985
Total liabilities$424,833$271,433
Shareholders' equity-$343,713-$47,241
Net debt—$124,581
Shares outstanding99.00M99.00M
Cash flow statement
Operating cash flow-$22,629-$123,077
Financing cash flow$0$119,250

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.